CYTOMED THERAPEUTICS LIMITED |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.07 USD | -2.36% |
|
+0.98% | -57.76% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 520K 710K | Sales 2025 * | 520K 710K | Capitalization | 24.46M 33.39M |
|---|---|---|---|---|---|
| Net income 2024 * | -1M -1.36M | Net income 2025 * | -1M -1.36M | EV / Sales 2024 * | 38.7 x |
| Net cash position 2024 * | 4.36M 5.95M | Net cash position 2025 * | 2.33M 3.18M | EV / Sales 2025 * | 42.6 x |
| P/E ratio 2024 * |
-10.6
x | P/E ratio 2025 * |
-10.6
x | Employees | - |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 29.27% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -2.36% | ||
| 1 week | +0.98% | ||
| Current month | -1.90% | ||
| 1 month | +2.48% | ||
| 3 months | -18.02% | ||
| 6 months | -49.01% | ||
| Current year | -57.76% |
1 week
1.95
2.16
1 month
1.952.48
Current year
1.924.90
1 year
1.929.25
3 years
1.929.25
5 years
1.929.25
10 years
1.929.25
| Managers | Title | Age | Since |
|---|---|---|---|
Wee Kiat Tan
CEO | Chief Executive Officer | 36 | 19-01-31 |
Yvonne Goh
DFI | Director of Finance/CFO | 35 | 20-02-29 |
Jieming Zeng
CTO | Chief Tech/Sci/R&D Officer | 51 | 19-07-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Chee Kong Choo
FOU | Founder | 65 | 18-03-08 |
Tao Wu
BRD | Director/Board Member | 59 | 23-04-17 |
Kei Wei Leong
BRD | Director/Board Member | 49 | 23-04-17 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-14 | 2.07 | -2.36% | 108 |
| 24-05-13 | 2.12 | -0.47% | 12,182 |
| 24-05-10 | 2.13 | +0.38% | 356 |
| 24-05-09 | 2.122 | -1.76% | 5,148 |
| 24-05-08 | 2.16 | +5.37% | 1,314 |
Delayed Quote Nasdaq, May 14, 2024 at 10:51 am
More quotes
CytoMed Therapeutics Limited is a pre-clinical biopharmaceutical company. The Company is focused on harnessing its licensed proprietary technologies to create cell-based immunotherapies for the treatment of human cancers. The development of its technologies has been inspired by the clinical success of existing CAR-T in treating hematological malignancies, as well as the clinical limitations and commercial challenges in extrapolating the CAR-T principle into treatment of solid tumors. It is developing three product candidates: CTM-N2D, iPSC-gdNKT and CTM-GDT. CTM-N2D is its lead product candidate, and it consists of expanded gamma delta T cells grafted with NKG2DL-targeting CAR to enhance anti-cancer cytotoxicity. Its second product candidate, iPSC-gdNKT, utilizes iPSC as a starting material to generate gdNKT, which is a synthetic hybrid of a gamma delta T cell and a NK cell. Its third product candidate, CTM-GDT, consists of expanded allogeneic gamma delta T cells.
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
2.12
USD
Average target price
5
USD
Spread / Average Target
+135.85%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -57.76% | 24.46M | |
| +4.46% | 111B | |
| +11.40% | 105B | |
| -12.32% | 22.34B | |
| -3.70% | 21.93B | |
| -6.03% | 18.59B | |
| -35.21% | 18.12B | |
| -9.99% | 16.96B | |
| +2.74% | 13.7B | |
| +36.92% | 12.45B |
- Stock Market
- Equities
- GDTC Stock